Key Insights

Highlights

Treatment Research

5 treatments under study, led by Xnw5004 Chidamide Placebo

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 2 (2)
Phase 3 (1)

Trial Status

Recruiting2
Not Yet Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06519526Phase 2RecruitingPrimary

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT06776952Phase 3RecruitingPrimary

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT06702605Phase 2Not Yet RecruitingPrimary

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Showing all 3 trials

Research Network

Common Treatments

  • Xnw5004 Chidamide Placebo1
  • Shr25541
  • Xnw5004 Tablets1
  • Xnw5004 Placebo Chidamide1
  • Shr03021

Active Sponsors

  • Evopoint Biosciences Inc.2
  • Fudan University1

Top Investigators

Activity Timeline